# Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

> **NCT01170962** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 512 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** BMS-790052
- **DRUG:** BMS-790052
- **DRUG:** Placebo
- **DRUG:** peginterferon alfa-2a
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01170962
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01170962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01170962, "Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01170962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*